A Non-interventional Study of Clinical Experience in Patients Prescribed Raxone® for the Treatment of Leber's Hereditary Optic Neuropathy (LHON)

Status: Completed
Location: See all (26) locations...
Intervention Type: Drug
Study Type: Observational
SUMMARY

This study is a multicentre, prospective, non-interventional post-authorisation safety study (PASS) of the clinical outcomes for patients with LHON treated with Raxone®. No medication will be provided as part of this study. Raxone® will be obtained through commercial channels.

Eligibility
Participation Requirements
Sex: All
Healthy Volunteers: No
View:

• Patient prescribed Raxone® for the treatment of LHON;

• Patient has completed an Informed Consent Form (ICF) indicating that he/she (or a legally acceptable representative) has been informed of all pertinent aspects of the study and has agreed to participate in the study;

• Patient is not participating in any interventional study.

Locations
Other Locations
Austria
Universitaetsklinikum Graz
Graz
Medical University of Vienna
Vienna
France
CHU Amiens - Centre Saint Victor
Amiens
CHU Angers - Hôpital Hôtel Dieu
Angers
Hopital Roger Salengro - CHU Lille
Lille
Hospices Civils de Lyon
Lyon
Hopital Neurologique Pierre Wertheimer
Lyon Cedex
CHU de Nîmes - Hôpital Carémeau
Nîmes
Centre Hospitalier National d'Ophtalmologie (CHNO) des Quinze-Vingts
Paris
Fondation Ophtalmologique Adolphe de Rothschild
Paris
Hôpital Européen Georges Pompidou
Paris
Germany
Universitaetsklinikum Essen
Essen
Universitaetsklinikum Freiburg
Freiburg
Universitaetsklinikum Hamburg-Eppendorf
Hamburg
Universitaetsklinikum Heidelberg
Heidelberg
Friedrich-Baur-Institut
Munich
Universitaetsklinikum Muenster
Munster
Dietrich-Bonhoeffer-Klinikum Neubrandenburg
Neubrandenburg
Universitaetsklinikum Regensburg
Regensburg
Julius Maximilians University
Wuerzburg
Greece
Athens Ophthalmological Center
Athens
Italy
Università di Bologna-Clinica Neurologica-Dipartimento di Scienze Neurologiche
Bologna
Ospedale San Raffaele
Milano
Azienda Ospedaliera S. Camillo Forlanini
Rome
Netherlands
Universitair Medisch Centrum Groningen
Groningen
Maastricht University Medical Center
Maastricht
Time Frame
Start Date: September 2016
Completion Date: April 16, 2021
Participants
Target number of participants: 229
Treatments
Patients who are treated with Raxone®
Sponsors
Leads: Santhera Pharmaceuticals

This content was sourced from clinicaltrials.gov